Media&ng rela&ons with industry Company presenta&on July 2011
FOCUSING THE MODEL IFOM and IEO joined forces to create in June 2010 a tech transfer opera-on which could also support business development for drug discovery and other transla&onal programs
IFOM and IEO at glance • The IFOM-‐IEO Campus is one of Europe’s largest research campus dedicated to Cancer Research with over 400 scien&sts and 4 PhD programs with 150 PhD students; • The IEO is a private research hospital with 320 MD and PhDs dedicated to preven&on, early diagnosis and therapy of cancer through advanced technology and medical prac&ces; • Since mid 2009, IEO has started an industry standard drug discovery program (DDP);
TTFactor MISSION Help IFOM and IEO improving and increasing solu7ons to medical needs of pa7ents while funding their research Advance scien7ﬁc results arising from the IFOM and IEO by suppor7ng the genera7on, protec7on and transfer of intellectual proper7es and know how to the for proﬁt sector through: – Technology licensing (Conﬁden7ality Ag., Term sheet, Due diligence); – Sponsored research agreements; – MTA (Material transfer Agreements); – and spin oﬀ crea7on.
TEAM Daniela Bellomo PhD MBA General ManagementMario Cesana MSc (Econ) Chief Financial OfficerGermano Ferrari PhD MBA Business DevelopmentMarzia Fumagalli PhD Intellectual PropertyMarilina Palmiotto LLP LegalJacopo Franchini BSc Business Development AssociateAurelia Ramunni Assistant Pier Giuseppe Pelicci, President - IEO Claudio Basilico - New York University Andrea Cuomo - ST Microelectronics Marco Foiani - IFOMBOARD OF Isaac Kohlberg - Harvard UniversityDIRECTORS Tomas Lindhal - FRS-Cancer Research UK Stefano Michelini - IEO Elisabetta Petrucci - FIRC Domenico Triarico - IEO Raffaela Zoboli - IFOM
ACTIVITIES FOCUSED TOWARDS FOCUSED TOWARDS EXTERNAL INTERNAL STAKEHOLDERS STAKEHOLDERSPATENTING EDUCATIONAL CAMPAIGN ON IPMARKETING SUPPORT INTERNALLICENSING OFFICES IN IP ISSUESSPONSORED RESEARCH BUSINESSSPINOFFS DEVELOPMENT FOR DDP
PATENT PORTFOFLIO AVAILABLE FOR LICENSING Please visit our web site www.ttfactor.com to look for new patent opportunities Subject Inves-gators Filed Descrip-on Biomarkers Pier Paolo Di Fiore at al. 2004 A novel cancer “signature” (10 genes or 80 genes) which helps to predict the course of disease and the choice of treatment in early stages of Lung Cancer Biomarkers Pier Paolo Di Fiore at al. 2005 Method for establishing suscep&bility to drug treatment in breast cancer for drugs ac&ng on Numb gene (GRANTED IN USA) Small Molecules Peter De Wulf et al. 2009 Novel an&-‐cancer compounds with an&tubulin eﬀect Small Molecules Saverio Minucci et al. 2010 Novel compounds with an&-‐tumor eﬀect inhibi&ng LSD1 and LSD2 histone demethylases for the treatment of tumors and viral infec&ons Tumor Immunotherapy Maria Rescigno et al. 2010 Method to improve the tumoral an&gen presenta&on to dendri&c cells by Salmonella infec&on for melanoma therapy or prophylaxis Screening Assay Ario De Marco et al. 2010 Assay for iden&fying agents ac&ng on cell growth (through eIF6) Biologics Nicolai Sidenius 2010 A novel “dual ac&on” type of inhibitor of the urokinase-‐type plasminogen ac&vator receptor (uPAR) Biomarkers Pier Paolo Di Fiore at al. 2010 A serum circula&ng miRNAs diagnos&c test to iden&fy asymptoma&c high-‐ risk individuals with early stages lung cancer (NSCLC) Diagnos-cs Marco Chinol et al. 2010 Novel radiopharmaceu&cals with an extended half-‐life for cancer diagnosis and therapy
Visit us at www.cactor.com Contact us at TTFactor s.r.l. Via Adamello, 16 20139 Milano T: +39 02 94375140 F +39 02 94375991 e-mail: email@example.com